PolyPid Regains European Rights to D-PLEX100 After ADVANZ PHARMA Deal Ends
PYPD sits 72% above its 52-week low of $3.06 on light trading volume (0.2× avg).
Summary
PolyPid and ADVANZ PHARMA mutually terminated their 2022 European license for D-PLEX100, returning exclusive commercialization rights to PolyPid. The European Medicines Agency has validated PolyPid’s Marketing Authorization Application for D-PLEX100. This follows the July Azurity deal for U.S./Canada rights and the FDA's Priority Review with a November 28 PDUFA date. Regaining Europe removes a legacy constraint and lets PolyPid seek a new partner for a major market, potentially on better terms given the positive Phase 3 data and regulatory progress. The company's cash position remains tight, so a new European deal could bring needed upfront payments. Watch for announcements of a new European partnership or licensing agreement.
At the time of this announcement, PYPD was trading at $5.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $107M. The 52-week trading range was $3.06 to $5.73. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.